Robert I. Blum - 15 Mar 2026 Form 4 Insider Report for CYTOKINETICS INC (CYTK)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
17 Mar 2026, 16:11:19 UTC
Prior SEC filing
10 Mar 2026
Next SEC filing
18 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ John O. Faurescu, attorney-in-fact for Mr. Blum

Key filing fact

Robert I. Blum filed Form 4 for CYTOKINETICS INC (CYTK) on 17 Mar 2026.

Key facts

  • This page summarizes Robert I. Blum's Form 4 filing for CYTOKINETICS INC (CYTK).
  • 3 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 17 Mar 2026, 16:11.

Change

  • Previous filing in this sequence was filed on 10 Mar 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001288859 Primary reporting owner

Blum Robert I

Relationship
President & CEO, Director
Address
350 OYSTER POINT BLVD, SOUTH SAN FRANCISCO
Signature
/s/ John O. Faurescu, attorney-in-fact for Mr. Blum
Signature date
17 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CYTK transaction

Common Stock

Award

Transaction value
Shares
+75,258
Change %
+19%
Price
$0.000000*
Shares after
466,931
Date
15 Mar 2026
Ownership
Direct
Footnotes
F1
CYTK holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
2,083
Date
15 Mar 2026
Ownership
by Trust 1
Footnotes
F2
CYTK holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
2,083
Date
15 Mar 2026
Ownership
by Trust 2
Footnotes
F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CYTK transaction Derivative

Incentive Stock Option (Right to Buy)

Award

Transaction value
Shares
+1,665
Change %
Price
$0.000000*
Shares after
1,665
Date
15 Mar 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,665
Exercise price
$60.06
Footnotes
F4
CYTK transaction Derivative

Non-Qualified Stock Option (Right to Buy)

Award

Transaction value
Shares
+111,864
Change %
Price
$0.000000*
Shares after
111,864
Date
15 Mar 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
111,864
Exercise price
$60.06
Footnotes
F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Annual equity award comprised of restricted stock units ("RSUs") that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 40% of the RSUs on the 1-year anniversary of the grant date, an additional 40% of the RSUs on the 2-year anniversary of the grant date, and the final 20% of the RSUs on the 3-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan.

Footnote F2

Shares held by The Bridget Blum 2003 Irrevocable Trust.

Footnote F3

Shares held by The Brittany Blum 2003 Irrevocable Trust.

Footnote F4

Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.

Footnote F5

Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .